Hubei Guangji Pharmaceutical Co., Ltd Class A

As of June 30, 2026, Hubei Guangji Pharmaceutical Co., Ltd Class A carries a market capitalization of 1.88B, placing it among publicly traded companies globally. Its enterprise value stands at 2.90B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Hubei Guangji Pharmaceutical Co., Ltd Class A has 346.75M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.92, and the price-to-book ratio stands at 3.14.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.51 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.90B versus a market cap of 1.88B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Hubei Guangji Pharmaceutical Co., Ltd Class A maintains a current ratio of 0.53, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 232.61, indicating elevated leverage, while an interest coverage ratio of -8.43 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Hubei Guangji Pharmaceutical Co., Ltd Class A posted a negative return on equity (ROE) of -49.72, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -15.95, reflecting losses generated across the asset base. The company generates approximately 525,589.56 in revenue per employee across its workforce of 1,222.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.61 indicates how many times Hubei Guangji Pharmaceutical Co., Ltd Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Hubei Guangji Pharmaceutical Co., Ltd Class A recorded an income tax benefit of -2.88M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -438.82M and -404.39M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Hubei Guangji Pharmaceutical Co., Ltd Class A's stock has declined approximately 23.20% over the past 52 weeks. The 50-day moving average sits at 6.44, while the 200-day moving average is 6.82.

Over the twelve months ended June 30, 2026, Hubei Guangji Pharmaceutical Co., Ltd Class A generated 642.53M in revenue and converted that into -404.39M in net income, yielding earnings per share of -1.26. EBITDA reached -441.48M, while operating income came in at -94.78M.

As of June 30, 2026, Hubei Guangji Pharmaceutical Co., Ltd Class A holds 265.00M in cash and equivalents against 1.32B in total debt, resulting in a net debt position of 529.83M. Total book value stands at 597.67M, with working capital of -701.06M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Hubei Guangji Pharmaceutical Co., Ltd Class A posted a gross margin of 24.21, reflecting its pricing power and cost economics. The operating margin of -14.75 and net profit margin of -62.94 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Hubei Guangji Pharmaceutical Co., Ltd Class A paid dividends of 0.14 per share. The dividend payout ratio of -10.65 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -1.16, meaning Hubei Guangji Pharmaceutical Co., Ltd Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Hubei Guangji Pharmaceutical Co., Ltd Class A's most recent stock split took place on May 29, 2020 with a 5:6 split ratio.

As of June 30, 2026, Hubei Guangji Pharmaceutical Co., Ltd Class A has an Altman Z-Score of 0.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.